For many years, the Ras signaling pathway has triggered both hope and frustration in the field of cancer research. In normal health, Ras signaling is central to the regulation of intracellular ...

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, ...

A tissue section from a mouse model of lung metastasis showing cancer cells (green) that have attracted and activated fibroblasts (red) to support the growth of a metastatic tumor. Image: Massagué Lab ...

Pancreatic ductal adenocarcinoma (PDAC) is characterized clinically by poor survival and mechanistically by KRAS- and autophagy-dependent growth. We and others previously demonstrated that inhibition ...

Verastem Oncology Inc. has entered into a discovery and development collaboration with Genfleet Therapeutics (Shanghai) Ltd. to advance three oncology discovery programs targeting RAS pathway-driven ...

Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company’s lead program, ...

Ras genes encode proteins that can cause cancer (or become oncogenic) when mutated. All Ras proteins are GTPases which act as molecular switches in the cell, regulating signaling pathways and other ...

Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...